Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.

Abstract:

:Recently proposed criteria for remission by a 'Remission in Schizophrenia Working Group' have generated considerable interest. We assessed rates, predictors, and correlates of remission in a sample of patients with first-episode schizophrenia treated with injectable, long-acting risperidone. This allowed us to examine remission among patients known to be receiving medication. This was a single-site open-label study in which 50 newly diagnosed cases of schizophreniform disorder or schizophrenia aged 16 to 43 years were treated with injectable, long-acting risperidone 25-50 mg every 2 weeks for 2 years. Remission, according to Remission in Schizophrenia Working Group criteria, was achieved in 64% of the patients. Of those achieving remission, 97% maintained this status until study completion. Remission was associated with greater improvements in other symptom domains, insight, and social and occupational functioning. Patients in remission received lower doses of antipsychotic medication, had fewer extrapyramidal symptoms, and a more favorable attitude toward medication. The results of this open-label study suggest that a majority of first-episode patients who receive long-acting injectable antipsychotic medication may achieve sustained remission. Double-blind-controlled studies using long-acting injectable antipsychotics in early psychosis are warranted to further test this.

authors

Emsley R,Oosthuizen P,Koen L,Niehaus DJ,Medori R,Rabinowitz J

doi

10.1097/YIC.0b013e32830c2042

subject

Has Abstract

pub_date

2008-11-01 00:00:00

pages

325-31

issue

6

eissn

0268-1315

issn

1473-5857

pii

00004850-200811000-00003

journal_volume

23

pub_type

临床试验,杂志文章
  • The beneficial effect of escitalopram on obsessive-compulsive-related musical hallucinations in elderly patients with hearing impairment: a case series.

    abstract::Musical hallucinations (MHs), characterized by the hearing of tunes, melodies, or songs, is a relatively under-recognized phenomenon among elderly individuals with hearing impairment. In some patients, MHs represent a complex psychopathological phenomenon, hallucinatory in content and obsessive-compulsive (OC) in form...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000037

    authors: Bergman J,Pashinian A,Weizman A,Poyurovsky M

    更新日期:2014-09-01 00:00:00

  • Fluvoxamine and tricyclic antidepressants (TCAs): how do the TCAs compare as "new" drugs with established fluvoxamine?

    abstract::The tricyclic antidepressants (TCAs) are still considered as first-line treatment for depression, despite the availability of the selective serotonin reuptake inhibitors (SSRIs). This paper considers the current situation in reverse by assuming that only the SSRIs, in particular fluvoxamine, are available and the TCAs...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Ashford JJ

    更新日期:1995-01-01 00:00:00

  • Efficacy of metformin for prevention of weight gain in psychiatric populations: a review.

    abstract::There is uncertainty with regard to the appropriate use of metformin for the prevention and management of second-generation antipsychotic-induced weight gain and metabolic abnormalities. We aim to systematically review the primary literature and to provide recommendations with regard to the use of metformin in psychia...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/YIC.0b013e32834d0a5b

    authors: Newall H,Myles N,Ward PB,Samaras K,Shiers D,Curtis J

    更新日期:2012-03-01 00:00:00

  • Plasma levels of 3-methoxy-4-hydroxyphenylglycol levels, number of hospitalization and cognitive function predicts the cognitive effect of atypical antipsychotic monotherapy in patients with acute schizophrenia.

    abstract::Although the effects of atypical antipsychotics with regard to improving neurocognitive function are not sufficiently high. The present study applied an atypical antipsychotic monotherapy for patients with acute schizophrenia to (1) examine the percentage of patients who respond well to this treatment, (2) explore the...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000293

    authors: Hori H,Yoshimura R,Katsuki A,Atake K

    更新日期:2020-03-01 00:00:00

  • Olanzapine-induced cerebral metabolic changes related to symptom improvement in schizophrenia.

    abstract::The pattern of brain metabolic changes produced by olanzapine has yet to be described, despite the theoretical and clinical interest of this new antipsychotic. We studied a group of 17 schizophrenic patients who underwent two fluoro-deoxyglucose-positron emission tomography (FDG-PET) studies under two different condit...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004850-200501000-00003

    authors: Molina V,Gispert JD,Reig S,Pascau J,Martínez R,Sanz J,Palomo T,Desco M

    更新日期:2005-01-01 00:00:00

  • The conundrum of depression clinical trials: one size does not fit all.

    abstract::In this paper we review the history of antidepressant (AD) development, since the discovery of imipramine in 1957 to the present day. Through this exploration we will show that the increasing placebo response is likely a red herring and that a higher magnitude of placebo response is not an adequate explanation for AD ...

    journal_title:International clinical psychopharmacology

    pub_type: 历史文章,杂志文章,评审

    doi:10.1097/YIC.0000000000000229

    authors: Khan A,Mar KF,Brown WA

    更新日期:2018-09-01 00:00:00

  • Treatment of generalized anxiety disorder with citalopram.

    abstract::Serotonin reuptake inhibitors (SSRI), such as venalafaxine and paroxetine, are used in the treatment of generalized anxiety disorder (GAD). Patients with GAD frequently have comorbid psychiatric disorders, such as depression. SSRIs are effective in the treatment of a variety of anxiety disorders and depression. Citalo...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004850-200205000-00002

    authors: Varia I,Rauscher F

    更新日期:2002-05-01 00:00:00

  • Pharmacotherapy for disordered sleep in post-traumatic stress disorder: a systematic review.

    abstract::Sleep disorders, such as insomnia and nightmares, are common problems in post-traumatic stress disorder (PTSD), exert a strong negative influence on the quality of life and are a great challenge for clinical psychiatry. Several studies have reported on the efficacy of drugs for the treatment of PTSD-related sleep diso...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-200607000-00001

    authors: van Liempt S,Vermetten E,Geuze E,Westenberg HG

    更新日期:2006-07-01 00:00:00

  • Differences in interactions of SSRIs.

    abstract::The SSRIs differ from each other with regard to their chemical structure, their pharmacokinetics and their potential for causing pharmacokinetic interactions through inhibition of species of the cytochrome P450 enzyme system. Cytochrome P450 (CYP) is a group of more than 30 different heme containing proteins in humans...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199809005-00009

    authors: Brøsen K

    更新日期:1998-09-01 00:00:00

  • The rationale for long-term antidepressant therapy.

    abstract::Most depressive disorders can be viewed as recurrent conditions that may reduce quality of life and productivity. Results of controlled clinical trials indicate that patients should receive 4-6 months of continuation therapy after remission of the acute phase of the illness. Patients at risk of recurrent episodes, how...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199300840-00004

    authors: Kasper S

    更新日期:1993-01-01 00:00:00

  • Effects of venlafaxine extended release on resilience in posttraumatic stress disorder: an item analysis of the Connor-Davidson Resilience Scale.

    abstract::The aim was to evaluate the efficacy of venlafaxine extended release (ER) on characteristics of resilience, measured by the Connor-Davidson Resilience Scale, in patients with posttraumatic stress disorder (PTSD). Data were evaluated from a randomized, 6-month, international, multicenter study of adult outpatients with...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/YIC.0b013e32830c202d

    authors: Davidson J,Baldwin DS,Stein DJ,Pedersen R,Ahmed S,Musgnung J,Benattia I,Rothbaum BO

    更新日期:2008-09-01 00:00:00

  • A novel approach to rater training and certification in multinational trials.

    abstract::Clinical trials are becoming increasingly international in scope. Global studies pose unique challenges in training and calibrating raters owing to language and cultural differences. Recent findings that poorly conducted interviews reduce study power, makes attention to raters' clinical skills critical. In this study,...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0b013e3280803dad

    authors: Jeglic E,Kobak KA,Engelhardt N,Williams JB,Lipsitz JD,Salvucci D,Bryson H,Bellew K

    更新日期:2007-07-01 00:00:00

  • Somnambulistic-like behaviour in patients attending a lithium clinic.

    abstract::The prevalence of somnambulistic-like behaviour related to treatment with lithium alone or in combination with other psychotropic medications was evaluated in patients attending a lithium clinic. A written questionnaire on somnambulistic-like behaviour was completed by 389 patients. Information was provided on the tim...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Landry P,Warnes H,Nielsen T,Montplaisir J

    更新日期:1999-05-01 00:00:00

  • Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder: a meta-analysis.

    abstract::The primary objective of this post-hoc analysis was to evaluate the effect of short-term treatment with desvenlafaxine versus placebo on sexual dysfunction (SD), assessed from Arizona Sexual Experiences Scale scores, in adult outpatients with major depressive disorder. Data from three randomized, double-blind, placebo...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000094

    authors: Clayton AH,Hwang E,Kornstein SG,Tourian KA,Cheng RF,Abraham L,Mele L,Boucher M

    更新日期:2015-11-01 00:00:00

  • Risperidone-induced retrograde ejaculation: case report and review of the literature.

    abstract::Medication adherence with antipsychotics is adversely impacted by the burden of untoward adverse effects. In particular, sexual side-effects may interfere with compliance, but are often underreported by patients. Sexual dysfunction related to hyperprolactinemia is commonly described, but ejaculatory disturbance due to...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-200403000-00009

    authors: Loh C,Leckband SG,Meyer JM,Turner E

    更新日期:2004-03-01 00:00:00

  • Duloxetine in the treatment of major depressive disorder: an assessment of the relationship between outcomes and episode characteristics.

    abstract::Duloxetine, an inhibitor of serotonin and norepinephrine reuptake, has been approved for the treatment of major depressive disorder. In this analysis, data from eight, double-blind, placebo-controlled duloxetine trials were pooled, and the response to duloxetine treatment (40-120 mg/day) was compared between patients ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/00004850-200609000-00007

    authors: Perahia DG,Kajdasz DK,Royer MG,Walker DJ,Raskin J

    更新日期:2006-09-01 00:00:00

  • Adverse effects of antipsychotic drugs.

    abstract::The side effects of antipsychotic drugs have always been a major concern for clinicians and the appreciation of their importance in the treatment of schizophrenia has increased steadily over the years. Epidemiological studies as well as trials of the prevention and treatment of antipsychotic side effects are the conse...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199501005-00005

    authors: Whitworth AB,Fleischhacker WW

    更新日期:1995-01-01 00:00:00

  • Hematological effects of lithium potentiation of carbamazepine in patients with affective illness.

    abstract::Hematological indices were measured in 8 patients with bipolar disorder during carbamazepine and carbamazepine-lithium combination treatment. Carbamazepine treatment was associated with limited reductions in white blood cell indices. Combined lithium-carbamazepine treatment reversed the reductions in total white cell ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-198801000-00004

    authors: Joffe RT

    更新日期:1988-01-01 00:00:00

  • Elective combined electroconvulsive and clozapine therapy.

    abstract::Clozapine therapy does not produce the rapid response that may be required in severely disturbed patients. The latter, not uncommonly, obstruct treatment by refusing to give blood for haematological monitoring or refusing to swallow tablets. Whereas electroconvulsive therapy (ECT) may be used for rapid behavioural con...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199903000-00002

    authors: James DV,Gray NS

    更新日期:1999-03-01 00:00:00

  • Which antidepressants have demonstrated superior efficacy? A review of the evidence.

    abstract::A review of published evidence of superior efficacy of a particular antidepressant in major depressive disorder may assist clinicians in making considered treatment choices. To identify such candidates, an international group of experts met to assess published evidence (identified through searches in Medline and Embas...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/YIC.0b013e3282eff7e0

    authors: Montgomery SA,Baldwin DS,Blier P,Fineberg NA,Kasper S,Lader M,Lam RW,Lépine JP,Möller HJ,Nutt DJ,Rouillon F,Schatzberg AF,Thase ME

    更新日期:2007-11-01 00:00:00

  • A detailed longitudinal analysis on the use of naltrexone in the treatment of bulimia.

    abstract::In accord with our auto-addiction opioid model, naltrexone was previously reported to be effective in the treatment of bulimia in a controlled double-blind clinical trial with a randomized cross-over design. This is a detailed longitudinal analysis over a 16 month period of one subject from that study. Attenuation in ...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-199510030-00006

    authors: Marrazzi MA,Kinzie J,Luby ED

    更新日期:1995-09-01 00:00:00

  • Effectiveness of parental training, methylphenidate treatment, and their combination on academic achievements and behavior at school of children with attention-deficit hyperactivity disorder.

    abstract::This study aimed to compare the effectiveness of parental training (PT), methylphenidate treatment (MPH), and the combination of PT and MPH treatment (PT/MPH) on school achievements in children with attention-deficit hyperactivity disorder (ADHD). Twenty eight ADHD patients (age: 10.1±1.11 years) were divided into thr...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/YIC.0000000000000218

    authors: Golubchik P,Hamerman H,Manor I,Peskin M,Weizman A

    更新日期:2018-07-01 00:00:00

  • An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder.

    abstract::The chronic course of major depressive disorder (MDD) often impedes the ability of patients to achieve full remission. Return of full functioning is a critical goal of antidepressant pharmacotherapy as the presence of residual depressive symptoms is associated with an increased risk of relapse. Treatment guidelines re...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/YIC.0000000000000121

    authors: Carrasco JL,Kornstein SG,McIntyre RS,Fayyad R,Prieto R,Salas M,Mackell J,Boucher M

    更新日期:2016-05-01 00:00:00

  • Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study.

    abstract::The effects of an abrupt interruption of agomelatine, a new melatonergic/serotonergic antidepressant, were explored in a double-blind, placebo-controlled study. Paroxetine was used as active control. After 12 weeks of double-blind treatment with agomelatine 25 mg/day or paroxetine 20 mg/day, sustained remitted depress...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1097/01.yic.0000137184.64610.c8

    authors: Montgomery SA,Kennedy SH,Burrows GD,Lejoyeux M,Hindmarch I

    更新日期:2004-09-01 00:00:00

  • A double-blind, placebo-controlled comparison of sertraline and dothiepin in the treatment of major depression in general practice.

    abstract::In a double-blind multi-centre study of general practice patients with DSM-III-R major depressive disorder, sertraline (50 or 100 mg/day) was compared with dothiepin (75 or 150 mg/day) and with placebo. There were 83, 96 and 90 patients evaluated in the respective treatment groups; treatment lasted 6 weeks. Patients w...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1097/00004850-199400920-00005

    authors: Doogan DP,Langdon CJ

    更新日期:1994-07-01 00:00:00

  • Toleration and safety of sertraline: experience worldwide.

    abstract::The clinical trial programme of sertraline, a selective serotonin re-uptake inhibitor, has shown the drug to have a favourable safety and toleration profile. In contrast, the tricyclic antidepressant, amitriptyline, produced a significant level of side effects, particularly anticholinergic. The side-effect profile of ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199112002-00007

    authors: Doogan DP

    更新日期:1991-12-01 00:00:00

  • Anxiogenic effect of yohimbine in healthy subjects: comparison with caffeine and antagonism by clonidine and diazepam.

    abstract::Three placebo-controlled double-blind and crossover trials were carried out to analyze the effects of oral yohimbine (YOH) 0.8 mg/kg on mood and performance in 16 healthy students. Subjective assessments (visual analogue scales, side-effects on questionnaire) and objective measurements (digit symbols, flicker fusion, ...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-198807000-00003

    authors: Mattila M,Seppala T,Mattila MJ

    更新日期:1988-07-01 00:00:00

  • A double-blind placebo-controlled trial of zopiclone 7.5 mg and temazepam 20 mg in insomnia.

    abstract::Zopiclone, a cyclopyrrolone with hypnotic properties was compared with temazepam and placebo in the treatment of insomnia. After a week's washout period, suitable subjects were allocated at random to zopiclone 7.5 mg or temazepam 20 mg or placebo for 2 weeks. Measurements of psychomotor function using the Leed's psych...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-199007000-00001

    authors: Ngen CC,Hassan R

    更新日期:1990-07-01 00:00:00

  • Use of mood stabilizers for hospitalized psychotic and bipolar disorder patients.

    abstract::Treatments given to patients with primary psychotic disorders include mood stabilizers (MSs) combined with other psychotropics, despite the limited evidence of efficacy, safety, and lack of regulatory approval. We analyzed records of 636 inpatients at the McLean Hospital (2002-2009), who were diagnosed with bipolar di...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0b013e328340c0de

    authors: Ventriglio A,Vincenti A,Centorrino F,Talamo A,Fitzmaurice G,Baldessarini RJ

    更新日期:2011-03-01 00:00:00

  • Safety and tolerability of duloxetine in elderly patients with major depressive disorder: a pooled analysis of two placebo-controlled studies.

    abstract::The objective of this study was to examine the safety and tolerability of duloxetine hydrochloride, a serotonin-norepinephrine reuptake inhibitor, in a large cohort of elderly patients with major depressive disorder. Data were pooled from 8-week and 12-week, double-blind, randomized, placebo-controlled trials of dulox...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/YIC.0b013e32835b09cd

    authors: Oakes TM,Katona C,Liu P,Robinson M,Raskin J,Greist JH

    更新日期:2013-01-01 00:00:00